Policy | August 27, 2025
GST rejig may impact competitiveness of medical devices: AiMeD
AiMeD noted that proposed GST changes—to either 5% or 18%—both present significant risks requiring carefully nuanced consideration
AiMeD noted that proposed GST changes—to either 5% or 18%—both present significant risks requiring carefully nuanced consideration
Delegates also visited Emami’s WHO-GMP-certified manufacturing plant and Zandu Foundation for Healthcare farms for hands-on exposure to quality practices,
The first pillar is advanced manufacturing, focused on upgrading existing CDMO
Guidelines aim to establish state-regulated veterinary blood banks
Dr. Reddy’s becomes the first pharmaceutical company to receive regulatory approval to launch Linaclotide in India under the brand name Colozo
Investment supports Company’s plans to manufacture the vast majority of advanced medicines in the U.S. to meet the needs of patients in the U.S.
Anthony brings more than 25 years of pharmaceutical development and CRO experience to his expanded role
The company is bringing precision therapies for gynaecological cancers
Mangalam Drugs and Organics receives repeat export order worth $ 21, 81,040
The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study
Subscribe To Our Newsletter & Stay Updated
